Clinical Trials Logo

Drug-Drug Interaction (DDI) clinical trials

View clinical trials related to Drug-Drug Interaction (DDI).

Filter by:
  • None
  • Page 1

NCT ID: NCT03432793 Completed - Clinical trials for Drug Drug Interaction (DDI)

Drug-Drug Interaction (DDI) Study for TD-9855

Start date: February 28, 2018
Phase: Phase 1
Study type: Interventional

This study is designed to assess the effect of fluvoxamine, itraconazole and smoking on the PK disposition of multiple doses TD-9855 in healthy male subjects. The study will also assess the relationship between caffeine PK and TD-9855 PK disposition in healthy male smokers and non-smokers.

NCT ID: NCT02169713 Completed - Healthy Subjects Clinical Trials

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects

Start date: May 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of solifenacin and mirabegron on the concentrations of tamsulosin HCl after combined dosing. This study will also evaluate the safety and tolerability of the combined administration of solifenacin, mirabegron and tamsulosin HCl.

NCT ID: NCT02138799 Completed - Healthy Subjects Clinical Trials

A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men

Start date: July 2013
Phase: Phase 1
Study type: Interventional

This study evaluates how a drug that alters liver enzymes (rifampin) affects the metabolism of enzalutamide in men by measuring concentrations of enzalutamide and its metabolites in plasma.

NCT ID: NCT02127034 Completed - Healthy Subjects Clinical Trials

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects

Start date: March 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of steady state solifenacin and mirabegron on the pharmacokinetics of co-administered steady state digoxin. This study will also evaluate the safety and tolerability of the combined steady state administration of solifenacin, mirabegron and digoxin.

NCT ID: NCT02083627 Completed - Healthy Subjects Clinical Trials

A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects

Start date: February 2013
Phase: Phase 1
Study type: Interventional

This study will assess the effect of multiple doses of fidaxomicin on the single dose pharmacokinetics of rosuvastatin in healthy male subjects. Determine the safety and tolerability of multiple doses of fidaxomicin in the presence of a single dose of rosuvastatin in healthy male subjects. Also determine the pharmacokinetics of multiple doses of fidaxomicin and its metabolite OP-1118.

NCT ID: NCT01943487 Completed - Healthy Subjects Clinical Trials

A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet

Start date: August 2009
Phase: Phase 1
Study type: Interventional

This study investigates the effect of the co-administration of verapamil on the steady-state pharmacokinetics (PK) of solifenacin succinate and tamsulosin given as a combination tablet, EC905.

NCT ID: NCT01797198 Completed - Healthy Subjects Clinical Trials

A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects

Start date: April 2012
Phase: Phase 1
Study type: Interventional

ASP3652 is being investigated as a novel treatment for chronic pelvic pain. This is a two-part study to investigate the drug-drug potential of ASP3652. Part I of the study evaluates the effect of gemfibrozil twice daily on the single dose of ASP3652. Part 2 evaluates the effect of multiple doses of ASP3652 twice daily on the single dose of repaglinide. Subjects participating in one part of the study may not participate in the other part.